Biotech | February 26, 2026
Gilead to acquire Arcellx in $7.8 billion bet on next-generation CAR T therapy
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
If approved, DTX401 would be the first treatment to address the disease at its root cause
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
The NDA filing is supported by results from the phase III evERA Breast Cancer study
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
Duvakitug was well tolerated and safety was consistent with the induction study
Iberdomide has the potential to be the first approved CELMoD agent
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
Subscribe To Our Newsletter & Stay Updated
